An IAT, or indirect antiglobulin test, is a blood test that checks whether your blood contains antibodies that could attack red blood cells. It’s one of the most common tests performed before a blood transfusion and during pregnancy. You might also hear it called an “indirect Coombs test,” named after the scientist who developed it.
The test looks specifically for antibodies floating freely in your blood serum, ones that haven’t yet attached to red blood cells but could. If those antibodies encountered incompatible red blood cells (from a transfusion or a developing baby), they could latch on and destroy them. The IAT catches that risk before it becomes a problem.
How the Test Works
The IAT works by mixing a sample of your blood serum with a set of known red blood cells in a lab. If your serum contains antibodies against those red blood cells, the antibodies will bind to them. On their own, though, antibody-coated red blood cells don’t look any different under the microscope. So the lab adds a second ingredient: antihuman globulin, a reagent that bridges antibody-coated cells together and causes them to visibly clump. That clumping, called agglutination, is the positive signal.
Most commercial versions of the test screen for two types of immune proteins: IgG antibodies and a complement protein called C3. These are the molecules most likely to cause red blood cell destruction in the body. The test has evolved from a simple tube-based method to a more sensitive gel microcolumn technique, which uses a small column of gel to separate clumped cells from free-floating ones, improving accuracy.
IAT vs. DAT: Two Versions of the Same Idea
The IAT is often mentioned alongside the DAT, or direct antiglobulin test (direct Coombs test). They look for the same basic thing, antibodies targeting red blood cells, but from different angles. The DAT checks whether antibodies have already attached to your red blood cells inside your body. It’s used when a doctor suspects your immune system is actively destroying your own red cells right now, as in autoimmune hemolytic anemia.
The IAT, by contrast, looks for unbound antibodies circulating in your serum. These are antibodies with the potential to cause problems if they encounter the wrong red blood cells. Think of the DAT as detecting damage already in progress, and the IAT as detecting a risk that hasn’t materialized yet. That forward-looking quality is what makes the IAT so valuable for transfusion safety and prenatal care.
Before a Blood Transfusion
The IAT plays a central role in making sure donated blood is safe for you. Before any transfusion, the lab performs what’s called a “type and screen”: your blood type is confirmed, and your serum is screened for unexpected antibodies using the IAT. If no antibodies are found and you have no history of red cell antibodies, a shorter compatibility check can replace the full crossmatch, cutting the process from up to 60 minutes down significantly.
If the screen does pick up antibodies, the lab runs additional testing to identify exactly which ones are present. This narrows the pool of compatible donor blood and ensures the units selected won’t trigger a transfusion reaction. In many countries, including India, a full Coombs crossmatch (which uses the IAT principle) is mandatory before any blood or blood components are issued.
During Pregnancy
The IAT is a routine part of prenatal care. Current guidelines call for an antibody screen at the first prenatal visit, typically around 12 weeks of gestation, alongside blood typing. The goal is to identify antibodies that could cross the placenta and attack the baby’s red blood cells, a condition called hemolytic disease of the fetus and newborn (HDFN).
HDFN is rare, but it can be serious. Maternal antibodies that cross the placenta may destroy fetal red blood cells or suppress the baby’s bone marrow from producing new ones. The antibodies the test looks for go beyond the familiar Rh factor. The screen also checks for antibodies against less well-known red cell markers like Kell, Duffy, and Kidd antigens, any of which can cause HDFN.
If the initial screen comes back negative, that’s reassuring, but testing isn’t necessarily over. For Rh-negative patients, a repeat screen is typically performed around 28 weeks before receiving Rh immune globulin, a preventive treatment that stops the mother’s immune system from developing anti-Rh antibodies in the first place. If the screen is positive at any point, the specific antibody is identified and then monitored with titration tests every two to four weeks. Titration measures the concentration of the antibody. Rising levels signal that the baby may need closer surveillance or specialized care from a high-risk obstetrician.
What Results Mean
A negative IAT means no unexpected antibodies were detected in your serum. For transfusion purposes, this is straightforward good news: compatible blood can be issued without additional steps. In pregnancy, it means there’s currently no antibody-related risk to the baby, though repeat testing may still be recommended later.
A positive IAT means antibodies were found. The next step is always identification, figuring out exactly which antibody is present and whether it’s clinically significant. Not all red cell antibodies are equally dangerous. Some are harmless at body temperature and unlikely to cause a reaction. Others, particularly antibodies against Rh, Kell, and certain Duffy and Kidd antigens, carry real risk and require careful management.
In a transfusion setting, a positive result means the blood bank will need to find antigen-negative donor units, blood that lacks the specific marker your antibodies would target. This can take longer, which is one reason the screen is done well before blood is actually needed whenever possible.
Factors That Can Affect Accuracy
Like any lab test, the IAT isn’t perfect. False negatives can occur when the amount of antibody in the sample is too low to produce visible clumping, or because of technical issues like poor centrifugation or weakened reagents. Certain antibody types, particularly IgA antibodies and low-affinity antibodies, are harder for the standard test to detect.
False positives can happen too. Non-specific clumping of red blood cells, over-centrifugation, or clotted samples can all mimic a true positive result. One particularly interesting interference comes from rheumatoid factor (RF), a protein found in 70 to 90 percent of people with rheumatoid arthritis and 15 to 35 percent of those with lupus. RF can either enhance or suppress the clumping reaction depending on its concentration relative to the antibodies being tested, leading to either false-positive or false-negative results. This is especially relevant for patients with autoimmune conditions who may need both transfusion support and accurate antibody screening. When the lab suspects RF interference, additional steps can be taken to neutralize its effect.
The degree of interference from RF doesn’t always correlate neatly with how much of it is present. It also depends on the subtype of the red cell antibodies involved, making it a complex variable for the laboratory to manage. For patients, the practical takeaway is that if you have rheumatoid arthritis or lupus and need a blood transfusion, your medical team will likely take extra care with compatibility testing.